Technical Analysis – USDJPY looks overbought after sharp ascent; bullish overall



USDJPY resumed its broad positive trend after the bulls drove aggressively to a five-year high of 116.33 on Tuesday, marking seven consecutive days of gains.

Despite the fast ascent, the pair could not close above the 116.11 limitation taken from late 2016 and start of 2017, with the price sliding back to the negative territory during the early trading hours today.

A deceleration cannot be ruled out in the coming sessions as the market seems to be trading in overbought waters according to the RSI and the fast Stochastics. Yet, the upward pattern in the market has yet to show any sign of weakness and the ascending trendline is still safely navigating the price action northwards. Hence, unless the bears press the price below that trendline currently seen at 114.00, any declines could be of minor concern and buyers could remain on board.

Before the bears reach that key line, the price may seek initially support within the 115.45 – 115.25 region and then somewhere between 114.65 and 114.45. Falling beneath 114.00, the spotlight will turn to the 113.20 handle.

Should the bull run continue, the door would open for the 117.00 psychological mark and the 261.8% Fibonacci extension of the 115.88 – 112.52 downleg at 117.36. Additional gains from here would clear the way towards the tough resistance of 118.65 from December 2016.

Summarizing, although the recent sharp pickup in USDJPY may lose pace in the short-term amid strengthening overbought signals, the upward trajectory could keep buying confidence intact, as long as the price holds above 114.00.

Latest News

Technical Analysis – Natural gas futures tick higher as bullish forces linger



Technical Analysis – USDCAD plummets but 200-day SMA caps downside


Technical Analysis – GBPJPY battling to keep its feet above trendline


Technical Analysis – JP 225 index defends bulls, but not out of the woods yet

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

We are using cookies to give you the best experience on our website. Read more or change your cookie settings.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.